LYMErix

LYMErix

Public health A Lyme vaccine comprised of lipidated recombinant OspA–outer surface protein A of Borrelia burgdorferi.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
Mentioned in ?
References in periodicals archive ?
There was also LYMErix, a vaccine for Lyme disease, which lasted less than four years before class-action lawsuits linking it to rheumatoid arthritis forced it off the market.
These same individuals acquired patents for vaccines, such as LYMErix, that failed to become routine preventive public health measures.
(7) Two recombinant monovalent vaccines were simultaneously developed by SmithKline Beecham (LYMErix) and Pasteur Merieux Connaught (ImmuLyme) in the 1990s.
Lymerix, developed to prevent Lyme disease, is the only vaccine ever licensed in the United States to prevent a tickborne disease in humans, but it was removed from the market during 2003 amidst poor sales and unsubstantiated reports of increased adverse events (16,17).
Less than a year after GSK introduced LYMErix in 1999, attorneys claimed the adult Lyme Disease vaccine caused arthritis.
Steere, then chief of rheumatology and immunology at Tufts School of Medicine, led the development of Lymerix, which proved 78 percent effective but had questionable long-term effects.
Antibiotics are effective during early stages of the disease, and a vaccine called LYMErix is now available.
Antibiotics are effective during early stages of the disease, and last year the FDA licensed LYMErix, the first vaccine against Lyme disease.
Lackluster demand has forced GlaxoSmithKline, maker of LYMErix, to pull the Lyme disease vaccine off the market.
The Food and Drug Administration approved LYMErix in 1998, and hundreds of thousands received the vaccine the following year.
Shoemaker also advocates the use of VCS to screen all patients "who want [the] Lymerix" vaccination for Lyme disease at his chronic fatigue center (14); he has written that "many asymptomatic patients with a history of Lyme ...
The Food and Drug Administration has approved an enzyme-linked immunosorbent assay for detecting Lyme disease antibodies that does not yield false-positive results in those patients who have already been vaccinated with the Lymerix vaccine.